• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

byMinjee Kim
April 13, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema attacks compared to patients receiving placebo treatment.

2. Donidalorsen shows an acceptable safety profile after four doses.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Patients with hereditary angioedema experience unpredictable swellings that could potentially be fatal. Donidalorsen is an antisense oligonucleotide treatment that inhibits the production of plasma prekallikrein, a key contributor to excessive vascular permeability. In this phase 2 trial, patients with hereditary angioedema with C1 deficiency were randomized in a 2:1 ratio to either receive four doses of donidalorsen or placebo treatment. The primary endpoint was the number of confirmed angioedema attacks per month between experimental groups. Secondary endpoints analyzed the number of moderate-to-severe attacks, prekallikrein levels, and impact on quality of life measures. The study found that at a 17-week follow-up, patients receiving donidalorsen experienced a lower rate of investigator-confirmed angioedema attacks per month compared to patients receiving placebo. This group also experienced an improvement in quality of life measures and a reduction in prekallikrein activity. Safety data demonstrate similar rates of adverse events in both groups with the most common event being headache and nausea. Taken together, this study supports the use of donidalorsen as a treatment for patients with hereditary angioedema and warrants further investigation on its safety and efficacy. The study is limited by its very small sample size and selection of patients with C1 inhibitor deficiency, limiting the generalizability of these results to all patients with hereditary angioedema.

Click to read the study in NEJM 

Relevant Reading: Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

RELATED REPORTS

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

Development and validation of PEN-FAST clinical prediction tool for possible penicillin allergy

In-Depth [randomized controlled trial]: In this small phase 2 randomized control trial, 20 patients with laboratory-confirmed hereditary angioedema with a C1 inhibitor deficiency (activity < 40%) were randomized in a 2:1 ratio to either receive 80 mg of donidalorsen or placebo treatment by subcutaneous injection on a schedule of 4 doses each spaced 4 weeks apart. Patients were then tracked for frequency and severity of investigator-confirmed angioedema attacks throughout the 17-week study. Secondary endpoints analyzed differences in frequency of moderate-to-severe attacks, attacks in the second half of the study, prekallikrein levels, and impact on quality of life measures. Differences in rates were analyzed using a Poisson regression model. The study found that the 14 patients who received donidalorsen had a mean monthly rate of 0.23 investigator-confirmed angioedema attacks (95% confidence interval [CI], 0.08 – 0.39), which was significantly lower than the 8 patients in the placebo group who had 2.21 (95% CI, 0.58 – 3.85). This represents a -90% mean difference between groups (95% CI, -96 to -76; P<0.001). With respect to secondary outcomes, patients receiving donidalorsen also demonstrate a reduction in moderate-to-severe attacks (-88%), decreased prekallikrein activity (-61%), and increased quality of life scores on the Angioedema Quality of Life Questionnaire. No serious adverse events were experienced by either group throughout the trial; however, mild adverse events were experienced by both groups with headache and nausea being the most common. Overall, the results of this small trial were able to support the use of donidalorsen in patients with hereditary angioedema and confirmed C1 inhibitor deficiency. Continued investigation for safety and efficacy in larger and longer trials is warranted.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemaangioedema attacksC1 inhibitorC1-inhibitor deficiencydonidalorsenhereditary angioedemakallikreinprekallikrein
Previous Post

Interatrial shunt device not effective in patients with symptomatic heart failure

Next Post

Sensorimotor religious and spiritual traditions may improve mental health outcomes

RelatedReports

Cardiology

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

March 22, 2022
Chronic Disease

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

March 16, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Infectious Disease

Development and validation of PEN-FAST clinical prediction tool for possible penicillin allergy

March 19, 2020
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Lanadelumab may be an effective prophylactic treatment for hereditary angioedema

December 12, 2018
Next Post
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Sensorimotor religious and spiritual traditions may improve mental health outcomes

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

Aspirin therapy linked to fewer cases of preeclampsia

Cessation of aspirin in older adults not associated with adverse health effects

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options